Comparison of Demitron and promethazin in treatment of nausea and vomiting in pregnancy

Comparison of Demitron and promethazin in treatment of hyperemesis gravidarum

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201298862N1

Enrollment

Registered

2012-10-09

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nausea and vomiting in pregnancy. Hyperemesis gravidarum with metabolic disturbance

Interventions

Intervention 1: intervention group:Amp demitron 8mg intramuscular q 8 hour for 48 hours. Intervention 2: control group:Amp promethazine 25mg intramuscular q 6hour for 48 hours.

Treatment - Drugs

intervention group:Amp demitron 8mg intramuscular q 8 hour for 48 hours

control group:Amp promethazine 25mg intramuscular q 6hour for 48 hours

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: inclusion criteria: pregnant women with gestation of 20 weeks or less; dehydration due to nausia and vomiting exclusion criteria: multiple pregnancy; nonviable pregnancy; concomitant emetogenic pathology associated with the symptomatology (hepatitis, gastrointestinal disorder,... )

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: 48 hours after drug beginning. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Drug adverse reactions. Timepoint: 48 hours after drug beginning. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYasamin Mehrolhasani(MD)

Kerman University of Medical Sciences

yasamin_m@yahoo.com+98 34 1281 4283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026